Product Information
CARBIDOPA-LEVO ER 50-200 TAB is a generic product labeled by BluePoint Laboratories, priced at $0.1812 per EA under NDC 68001017200. Its NADAC has been published 621 times since Apr 9, 2014.
FDA first approved this application on Feb 8, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
50; 200 mg/1; mg/1
Manufacturer
BluePoint LaboratoriesNDC
68001017200
Classification
Generic
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Effective Date
2/18/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA202323FDA Approved
2/8/2013
TE Code
AB
On Market Since
1/22/2014
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVO ER 50-200 TAB has been published 621 times since Apr 9, 2014, and over the history we have for it it has declined 60.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1812 per EA |
|---|---|
| All-time high | $0.6666 (May 13, 2015) |
| All-time low | $0.1551 (May 22, 2024) |
| 52-week high | $0.2155 |
| 52-week low | $0.1812 |
| Median price | $0.3709 |
| Average price | $0.3508 |
| Largest weekly change | +52.4% (Jun 19, 2024) |
| Weeks tracked | 621 |
| Tracking since | Apr 9, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
0.0%
1Y
-15.9%
3Y
-37.2%
5Y
-49.5%
All
-60.6%
Last surveyed Feb 25, 2026 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 4% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVO ER 50-200 TAB?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO ER 50-200 TAB, manufactured by BluePoint Laboratories, is $0.1812 per EA (NDC 68001017200), effective Feb 25, 2026.
How has the price of CARBIDOPA-LEVO ER 50-200 TAB changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVO ER 50-200 TAB has declined 60.6%. It has been tracked across 621 weekly CMS publications since Apr 9, 2014.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO ER 50-200 TAB?
Since Apr 9, 2014, the NADAC for CARBIDOPA-LEVO ER 50-200 TAB has ranged from a low of $0.1551 (May 22, 2024) to a high of $0.6666 (May 13, 2015), with a median of $0.3709 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVO ER 50-200 TAB?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBIDOPA-LEVO ER 50-200 TAB, is $0.1735 per EA — about 4% below CARBIDOPA-LEVO ER 50-200 TAB.
Who manufactures CARBIDOPA-LEVO ER 50-200 TAB?
CARBIDOPA-LEVO ER 50-200 TAB (NDC 68001017200) is labeled by BluePoint Laboratories, and CMS classifies it as a generic product.